Federal Circuit Doubles-Down on Vanda, Highlighting Limitations of § 101 Defense
Last week, the Federal Circuit reversed a decision from the District of Delaware that held that a method of treatment patent invalid under 35 U.S.C. § 101. Endo Pharms. Inc. et al. v. Teva Pharms. USA et al. The claim at issue recited: A method of treating pain in a renally impaired patient, comprising the steps…